AustinPx invests in pharmaceutics and manufacturing capabilities to accelerate drug development

April 11, 2024

Remove from favorites

Add to favorites

AustinPx, a prominent contract development and manufacturing organization (CDMO) focusing on enhancing the bioavailability of orally delivered small molecule drug candidates, has announced the acquisition of cutting-edge equipment to bolster its early phase development and manufacturing capabilities.

The newly acquired technologies include the 3P Innovations API capsule filling machine, FT4 Powder Rheometer®, and the STYL’One Nano compaction simulator. These investments aim to accelerate timelines, enhance stability, and mitigate risks.

Elizabeth Hickman, AustinPx's chief business officer, emphasizes the importance of offering cost-effective services to meet the industry's demands for efficiency without compromising quality. The Fill2 Weight Gravimetric Filler facilitates precise filling of capsules and bottles with minimal API, facilitating rapid transition to clinical trial material manufacturing. The FT4 Powder Rheometer provides critical insights into powder flow properties, aiding formulation optimization and process efficiency. The STYL’One nano compaction simulator streamlines tablet development and minimizes scale-up risks.

Justin Keen, Senior Vice President of Operations, highlights the significance of these technologies in fostering innovation and ensuring clients' success. These enhanced capabilities mark a significant milestone in AustinPx's growth trajectory, reinforcing its position as a leading CDMO in the pharmaceutical industry.